Solventum Corporation $SOLV Shares Purchased by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. increased its holdings in Solventum Corporation (NYSE:SOLV) by 1,414.5% during the second quarter, Holdings Channel reports. The firm owned 24,990 shares of the company’s stock after purchasing an additional 23,340 shares during the period. TD Waterhouse Canada Inc.’s holdings in Solventum were worth $1,958,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of SOLV. CrossGen Wealth LLC acquired a new position in Solventum in the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in Solventum in the 3rd quarter worth about $25,000. CYBER HORNET ETFs LLC bought a new position in Solventum during the second quarter valued at approximately $28,000. Modus Advisors LLC bought a new position in shares of Solventum during the 4th quarter valued at $30,000. Finally, Clearstead Trust LLC raised its holdings in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares in the last quarter.

Solventum Price Performance

NYSE:SOLV opened at $90.21 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a market cap of $15.36 billion, a PE ratio of 11.03, a price-to-earnings-growth ratio of 1.43 and a beta of 0.61. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $94.16. The company’s 50-day moving average price is $84.53 and its two-hundred day moving average price is $76.25.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm earned $1.69 earnings per share. The business’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities analysts anticipate that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SOLV has been the subject of a number of analyst reports. KeyCorp boosted their price objective on shares of Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Piper Sandler raised their price objective on Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Wedbush upped their price objective on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, August 22nd. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Solventum has a consensus rating of “Moderate Buy” and an average target price of $91.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.